NCT04150900View on ClinicalTrials.gov

1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 13, 2020

Primary Completion Date

September 1, 2024

Study Completion Date

January 1, 2027

Conditions
Squamous Cell Carcinoma
Interventions
DRUG

Bavituximab

Bavituximab is a chimeric (human/mouse) monoclonal antibody (mAb) derived from murine mAb 3G4 that targets phosphatidylserine (PS) after binding to β2-glycoprotein 1 (β2-GP1).

DRUG

Pembrolizumab

Pembrolizumab is a highly selective humanized mAb designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

Trial Locations (1)

21201

University of Maryland Medical Center, Baltimore

All Listed Sponsors
lead

University of Maryland, Baltimore

OTHER